The full edition of the report is available at Xinhua Silk Road Database. You can click the “Table of Content” to have a general understanding of it.
Click on the button below to create your account and get immediate access to thousands of articles.
Chinese pharmaceutical firm wins FDA's provisional approval for sales of generic anti-stroke drug in U.S. market
Zhejiang Huahai Pharmaceutical Co., Ltd. (Huahai Pharmaceutical, 600521.SH) announced on Wednesday that its Abbreviated New Drug Application (ANDA) for Apixaban Tablets submitted to the U.S. Food and Drug Administration (FDA) has been temporarily approved.
April15,2022
Zhejiang Huahai Pharmaceutical tablet application receives FDA clearance
Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SH) announced Friday that its abbreviated new drug application (ANDA) for 50mg doxycycline hydrochloride sustained-release tablets had gotten the approval of the U.S. Food and Drug Administration (FDA ).
February22,2019
Hunan Jingfeng Pharmaceutical gets U.S. FDA approval, qualified to sell prednisone tablets
Hunan Jingfeng Pharmaceutical (000908.SZ) announced Thursday that it had received approval from the U.S. Food and Drug Administration (FDA) for its prednisone tablet ANDA application.
December07,2018
If you have any questions, please enter them in the box below.
Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to silkroadweekly@xinhua.org and share your stories with more people.
Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.
